Make your drugs soluble with Dispersome®

Enhanced Bioavailability
Applicable to a wide range of drugs
Based on natural, safe excipient

Dispersome® - An enabling technology for low solubility drugs

DISPERSOME® PLATFORM

Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.

IMPROVING OUTCOMES

By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.

COMPATIBLE TECHNOLOGY

Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.

Advancing with Dispersome® Technology

Some of our industry partners. We are delighted to have established partnerships with prominent pharmaceutical companies that have adopted our Dispersome® Technology. These valued collaborations underscore our commitment to advancing drug solubility, positively impacting patient well-being, and shaping the future of drug delivery.

Learn more  →

Zerion Pharma News

lab equipment
Press Releases
|
February 15, 2024

dsm-firmenich and Zerion Pharma form a partnership to develop improved cannabinoids

First Cannabidiol drug formulation from partnership to enter clinical studies in 2024.

____________________
lab equipment
Zerion in the news
|
October 17, 2023

Zerion Pharma featured in Pharmaceutical Technology

Zerion Pharma is featured as an innovative start-up by Pharmaceutical Technology in their ‘Trends in Formulation 2023’ eBook, October 2023.

____________________
lab equipment
Press Releases
|
September 25, 2023

Zerion Pharma A/S elects Carl-Åke Carlsson as Chairman of the Board

September 25, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces that the Company has elected Mr. Carl-Åke Carlsson as its new Chairman of the Board of Directors.

____________________
More news